Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG vs Epirubicin in Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT05146635Unknown
- Sponsor
- Mansoura University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing Intravesical immunotherapy (BCG) group with Intravesical chemotherapy (Epirubicin) group (2 arms). Primary endpoints: Tumor recurrence rate at 2 years and Tumor Progression rate at 2 years. Status: unknown.
02
Drugs
bcg vaccineepirubicin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05146635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146635.